Trials / Completed
CompletedNCT03772600
Comparing Continuous With Flash Glucose Monitoring in Adults With Type 1 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 269 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study wants to compare the Dexcom G6® continuous glucose monitoring (CGM) system (experimental group) with the FreeStyle Libre flash glucose monitoring (FGM) system (control group). The ALERTT1 trial will have three phases: a baseline, study, and extension phase. During the baseline phase, eligible patients will be screened for in- and exclusion criteria, wear a blinded Dexcom G6® for 28 days, together with their FreeStyle Libre FGM system, and receive a uniform education moment. In the study phase, patients will be randomized into two groups (1:1): the experimental group will use an unblinded Dexcom G6® CGM for 6 months, the control group will keep using the FreeStyle Libre FGM system for 6 months. Before the 6 month time point is reached, patients in the control group will wear a blinded Dexcom G6® CGM for 28 days, together with their FreeStyle Libre FGM. In the extension phase, patients in the initial control group will start using unblinded Dexcom G6® for 30 months. The initial experimental group will keep using the unblinded Dexcom G6® for the next 30 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Dexcom G6 CGM | Use of Dexcom G6 |
Timeline
- Start date
- 2019-01-29
- Primary completion
- 2020-10-01
- Completion
- 2022-11-30
- First posted
- 2018-12-11
- Last updated
- 2022-12-21
Locations
6 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03772600. Inclusion in this directory is not an endorsement.